Women over 40 are ditching expensive eye creams for this natural serum that works in seven days

If you've ever stared down a $300 eye cream that promised miracles and delivered, well, moisturiser, you're not alone.
Crow's feet, dark circles, puffiness, they don't care how much you spend.
But what if one tiny bottle of oil was quietly outshining the luxury labels and delivering real results in just seven days?
Know the news with the 7NEWS app: Download today
That's where the 100 per cent Pure Prickly Pear Eye Roller Bottle from Indagare Natural Beauty is $49.
It's the natural, non-toxic serum thousands of Aussie women over 40 swear by, and it's making serious waves for being that product, the one that actually works.
And the best part is that it's made from one of the world's most expensive oils, but still comes in at under 50 bucks.
What's the deal with Prickly Pear Seed Oil?
You've probably heard of argan oil, but prickly pear seed oil is its overachieving cousin, and it's finally getting the spotlight it deserves.
With 150 per cent more vitamin E than argan, this ultra-luxe oil is rich in antioxidants, ultra-hydrating, and packed with skin-loving nutrients.
The Prickly Pear Eye Roller from Indagare doesn't just rely on marketing hype.
It's backed by serious skin science and thousands of glowing 5-star reviews.
Users say it reduces puffiness, smooths fine lines, and brightens tired under-eyes with visible results in as little as one week.
Let that sink in, visible results, one week, $49.
It's not just what's in the bottle, it's what's not.
This serum is 100 per cent certified organic, cruelty-free, non-toxic, free from synthetic fragrances, parabens, and silicones and packaged in a genius rollerball bottle for targeted application.
No need to dip fingers into pots or waste a drop, just glide it under the eyes (and even over lips) morning or night.
It's handbag-friendly, travel-friendly, and sleep-deprived-woman-friendly.
'My skin looks better than it did 5 years ago.'
That's what Catherine, Indagare's founder and a self-described skincare sceptic, had to say about this game-changing oil.
'I've tried every premium eye cream out there, and this is the only one that actually made a visible difference,' she says. 'My fine lines have softened, the puffiness is down, and I actually look less tired. I even use it around my lips. It's become my holy grail.'
Other users agree. The reviews
'This is the first thing I've ever used that actually works.'
'My dark circles are fading, and I finally look awake again.'
'Seven days in and my under-eye bags are gone!'
Believe the hype
If your skincare shelf is full of broken promises, this may be the one product that finally delivers. With real, visible results and a clean, ethical formula, it's no wonder this little roller is making such a big impact.
Want to try it for yourself?

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

West Australian

3 days ago

• West Australian

ASX Runners of the Week: Amplia, archTIS and Vanadium Resources

If you were looking for correlation between the seemingly continuous breakouts of military hostilities between nuclear-armed nations and the market - good luck. The ASX continued at near all-time highs this week, pulling back a fraction by Friday, as conflict between Iran and Israel continued to rise. The oil price surged a further 10 per cent this week as Israel turned its focus from Iran's nuclear facilities to targeting its oil and gas infrastructure. Uranium stocks were the week's main winners. Surprisingly, they were not fuelled directly by global drivers, but rather by investment heavyweight Sprott's physical uranium trust purchase of $200 million worth of uranium oxide, which was announced on Monday. The result for uranium stocks on the index was deafening. Uranium miners Boss Energy, Paladin Energy and Deep Yellow were among the most heavily shorted on the ASX, making up three of the top 10 shorted companies. A sharp increase in uranium caused a two-fold effect of en masse buying and short seller panic to close out positions, with the big three uranium stocks all surging up 20 per cent on the day. In a rare shake-up, no Australian-based resource companies feature on this week's Bulls N' Bears' ASX Runners list. Instead, the chocolates went to a groundbreaking Aussie biotech story, which could be on to the makings of one of the biggest breakthroughs in oncology treatment in years. AMPLIA THERAPEUTICS (ASX: ATX) Up 339% (5.7c – 25c) This week's Bulls N' Bears ASX Runner of the Week is biotech trailblazer Amplia Therapeutics, which sent the market into an absolute tailspin thanks to a jaw-dropping set of results from a clinical trial for incredibly nasty pancreatic cancer. On Monday, the company announced a pathological complete response – no detectable signs of cancer - in a patient enrolled in its ACCENT trial of a drug therapy to limit tumour growth. The trial combined the therapy narmafotinib with two other drugs to treat a patient with metastatic (stage IV) pancreatic cancer. After surgery, the patient's primary and metastatic tumours showed no live cancer cells, a unicorn-rare outcome in this brutal disease, where no detectable cancer signs are less common than a sunny day in Melbourne. The market mumbled and murmured through Wednesday, then stacked 42 per cent onto Amplia's share price. Thursday brought a different tune: a second patient, out of 55 enrolled in the trial, achieved a confirmed complete response, with all tumour lesions vanishing for more than two months. In advanced pancreatic cancer, where one complete response in 431 patients is headline-worthy, two in a trial appears groundbreaking. The market lost its collective marbles and the company's shares rocketed to 25 cents per share – up 339 per cent - on Friday with more than $30 million in shares traded on the week. The move also delivered a handy little profit for Amplia's second largest shareholder Acorn Capital, which picked up a further $350,000 worth of shares on Monday, when it saw value before the broader market. Pancreatic cancer is Australia's eighth most common cancer and has a dismal 12.5 per cent five-year survival rate. With United States Food and Drug Administration registration already in the bag, Amplia's drug looks to be on the charge to transform oncology, especially as healthcare systems globally grapple with rising cancer burdens and demand for precision therapies. ARCHTIS LTD (ASX: AR9) Up 287% (6.2c – 24c) Taking out silver on this week's Runners list is cybersecurity expert archTIS Limited, which saw its share price catapult 390 per cent by Wednesday, before the ASX killjoys slammed it into suspension, ending any hopes the company could take out the coveted Bulls N' Bears podium. The company released a duo of blockbuster defence contracts on Monday and Wednesday, before archTIS' management rubbed shoulders with some of the world's cybersecurity elite. On Monday, the company unveiled a US Defence Department contract for 1000 licences for its NC Protect data security software, worth $38,500 a pop for six months, to lock down sensitive data in Microsoft's DoD365 cloud. After months of brutal testing by the prime global contractor, NC Protect came up trumps as the only integrated solution for robust, scalable attribute-based access control. ArchTIS says its product could address a potential 150,000-user rollout across the warfighter network, if it proves a success for the defence department. Amazingly, $100,000 worth of shares traded on Monday, before going supersonic on Tuesday, to push the company's share price up 100 per cent from last week's close on $600,000 shares traded. ArchTIS dropped a second bomb on Wednesday, announcing a three-year $263,185 deal for 400 users with a United Kingdom-based aerospace and defence titan, which is poised to be a blueprint for more than 100,000 potential users in a global Microsoft 365 rollout. The company's share price hit a peak of 24c for a gain of 287 per cent this week, on $1.4 million in intraday trading, before the compliance overlords at the ASX cried 'disorderly market' and placed the company into suspension, where it remains. It's likely a few day traders were caught flat-footed by the suspension and were no doubt scouring around to come up with the cash to settle on trades they had hoped to flip by market close on Wednesday. In a world where cyberattacks are spiking, archTIS' NC Protect could fulfil a crucial defence need. Its ability to secure sensitive communications in cloud environments, such as the DoD365 and Microsoft 365 platforms, is critical as nations race to shield their military and industrial data from state-sponsored threats. With geopolitical tensions boiling and the US and UK doubling down on cybersecurity to protect their defence industrial bases, archTIS' tech is perfectly timed to cash in on the global push for ironclad digital fortresses, making it a potential darling in the market and of Western military alliances. VANADIUM RESOURCES LTD (ASX: VR8) Up 185% (1.3c – 3.7c) Snagging the final spot on the Runners of the Week podium is the aptly named critical minerals developer Vanadium Resources, which shot out of a cannon on Tuesday, after inking a non-binding memorandum of understanding (MoU) with China Precious Asia (CPA). Vanadium will supply 1.2 million tonnes per annum of vanadium-rich magnetite direct shipping ore to the heavyweight global metals trader from its world-class Steelpoortdrift vanadium project in South Africa. The MoU positions Vanadium to tap into early cash flows at the fully permitted Steelpoortdrift, a behemoth resource with 680 million tonnes of ore at 0.70 per cent vanadium oxide, which is equivalent to 4.74Mt contained vanadium. That rate is enough to keep the company's lights on for more than 180 years. CPA will handle loading and collection of the direct shipping ore, with Vanadium retaining a nimble ±25 per cent supply flexibility each month, kicking off by December this year. Management believes the material positive operating cash flows will fast track its development, with good reason. Steelpoortdrift's vanadium-rich ore also brims with iron-rich magnetite, making it a dual-treat commodity in the Asian steel market. The news sent the company's long-beleaguered share price soaring a cheeky 185 per cent from last Friday's 1.3c close to a 3.7c peak on $230,000 in stock traded. Vanadium is also actively sniffing out profit-share deals and acquisitions to bolster its near-term game plan without derailing the direct shipping ore opportunity. The deal looks beneficial for both parties as vanadium supplies are projected to be in global deficit this year, coupled with China's ambitions to diversify from its dependence on Australian-based iron ore. Steelpoortdrift's high-grade, low-cost direct shipping option has reignited global and now market interest in the company. If Vanadium can lock in a binding agreement with CPA, this plucky minnow could vault into the vanadium big league and potentially self-fund its own mine development. Is your ASX-listed company doing something interesting? Contact:

7NEWS

4 days ago

• 7NEWS

Doctors sound alarm over microplastics as health and environmental fears mount

Microplastics have infiltrated nearly every corner of life — they're in our food and drinks, in the clothes we wear, and even in the air we breathe. Even newborns aren't immune, according to former Australian Medical Association president, Steve Robson. '(Microplastics) been detected in breast milk and even in baby poo of newborn babies,' professor Robson told 7NEWS, adding they 'can even affect our reproductive system'. 'What it's doing to our bodies is really frightening me.' A growing body of research has experts sounding the alarm on the potential health impacts of microplastic exposure. The University of Sydney published a major study on the topic showing that microplastics are 'building up in all types of tissues and cells within the human body'. 'Also with the digestive system, we found links to characteristics associated with cancer,' said the university's senior research fellow, Nicholas Chartres. 'We also found that they also impact things like respiratory health — so lung function — but also increasing chronic inflammation in the lung and also again with potential links to things like lung cancer.' An international treaty involving 175 countries is currently being finalised to combat global plastic pollution. But Chartres and a team of leading experts say environmental action must be matched with policies to protect human health. The are calling for a global cap on plastic production and legally binding requirements to ensure plastics are free from toxic chemicals, and taken aim at big companies and countries who are delaying reforms. 'We can't recycle our way out of the problem,' Chartres told 7NEWS. 'All we're doing essentially is continuing the cycle of exposing ourselves to these hazardous chemicals.' The team has also called attention to single-use plastics in healthcare, which surged during the COVID-19 pandemic. Robson says a review into healthcare is important. 'We need to think really carefully about how to refocus the health system to minimise the risk to patients and to the staff providing care,' Robson said. If the world fails to act, experts have predicted a dire future. 'Unfortunately, for generations to come there is going to be a growing burden of disease due to plastics,' Chartres said.

Perth Now

5 days ago

• Perth Now

Princess Catherine pulls out of Royal Ascot 'at the last minute'

Catherine, Princess of Wales pulled out of attending Royal Ascot "at the last minute" on Wednesday (18.06.25). The 43-year-old royal was expected to join her husband, Prince William, King Charles and Queen Camilla in the traditional carriage procession at the Berkshire racecourse. However, she is believed to have cancelled the engagement as she tries to "find the right balance" amid her gradual return to royal duties, following her battle with cancer. Royal correspondent Chris Ship shared to X: "Prince William will be at @Ascot today as expected but the Princess of Wales has decided, at the last minute, not to attend today. Ascot had previously named her in the second carriage. "It's understood she's decided to find the right balance as she returns to public engagements." Catherine was present at the Trooping the Colour event at Horse Guards Parade in London on Saturday (14.06.25). The princess underwent abdominal surgery in January 2024 and later revealed she was undergoing preventative chemotherapy, before confirming in January this year that she was in remission. Catherine - who has Prince George, 11, Princess Charlotte, 10, and Prince Louis, seven, with the future king - revealed she was cancer-free as she paid tribute to the staff at the Royal Marsden Hospital in west London, where she received treatment. She wrote on her and William's social media channels: "I wanted to take the opportunity to say thank you to The Royal Marsden for looking after me so well during the past year. "My heartfelt thanks goes to all those who have quietly walked alongside William and me as we have navigated everything. "We couldn't have asked for more. The care and advice we have received throughout my time as a patient has been exceptional. "In my new role as Joint Patron of The Royal Marsden, my hope is, that by supporting groundbreaking research and clinical excellence, as well as promoting patient and family wellbeing, we might save many more lives, and transform the experience of all those impacted by cancer. "It is a relief to now be in remission and I remain focussed on recovery. As anyone who has experienced a cancer diagnosis will know, it takes time to adjust to a new normal. I am however looking forward to a fulfilling year ahead. There is much to look forward to. Thank you to everyone for your continued support. C (sic)" The princess went public with her cancer diagnosis in March 2024, and praised her husband for his support. She said at the time: "It has taken me time to recover from major surgery in order to start my treatment. But, most importantly, it has taken us time to explain everything to George, Charlotte and Louis in a way that is appropriate for them, and to reassure them that I am going to be OK. "As I have said to them; I am well and getting stronger every day by focusing on the things that will help me heal; in my mind, body and spirits. "Having William by my side is a great source of comfort and reassurance too. As is the love, support and kindness that has been shown by so many of you. It means so much to us both."